Ibrahim Qazi

Ibrahim Qazi is a seasoned professional in clinical science with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as the Senior Director of Clinical Science at TORL BioTherapeutics, LLC since February 2024, Qazi previously held a similar role at IGM Biosciences, Inc. from October 2020 to February 2024. Notable prior positions include Associate Director of Clinical Science at BeiGene and Clinical Scientist at Five Prime Therapeutics, Inc. Qazi began a career in clinical development as a Clinical Development Fellow at MedImmune. Additional experience includes roles as an Ambulatory Care Pharmacist and Pharmacy Intern at Kaiser Permanente, as well as a Research Scientist at Wyeth. Academically, Qazi holds a Doctor of Pharmacy (Pharm.D.) from the University of Maryland Baltimore, a Master's in Chemistry from Stevens Institute of Technology, and a Bachelor's in Chemistry from the University of Pittsburgh-Johnstown. Expertise encompasses the design and interpretation of clinical trials in oncology and autoimmune diseases.